Sergernne York

Statistics

Publications

Citations

995

H-Index

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Sergernne York is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and hematologic malignancy therapy.

Publications per year

1996–2013

Publications

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology · 2012 · 412 citations

Medicine, Immunology, Oncology +14

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · Cancer · 2013 · 302 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O’Brien, Jeffrey L. Jorgensen et al. · Blood · 2011 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +6

Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms

Farhad Ravandi, Ahmed Aribi, Susan O’Brien et al. · Journal of Clinical Oncology · 2009 · 79 citations · Full text

Pharmacy, Immunology, Oncology +5

Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.

Roger S. Rittmaster, H Zwicker, Elizabeth Abbott et al. · The Journal of Clinical Endocrinology & Metabolism · 1996 · 39 citations · Full text

Medicine, Endocrinology, Pharmacology +11

1–5 of 7